Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements
New Findings Call the Precision of CRISPR-Cas9 Gene Editing into Question
CAR T Cells Show Solid Progress
Tumors are Being Deprived of Cover by New CAR T-Cell Technologies
Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
Blood Protein Linked to Mental Disorders
Consciousness-Aiding Protein Produced by Cells Deep in the Brainstem
For full access to this article login to GEN Select now.
Quantifying Downstream Capacity Crunch
Column Resins Are Implicated by Many Experts As the Source of Biomanufacturing's Woes
- In today’s biomanufacturing environment, downstream capacity has become a partial roadblock to nearly all CMOs (94%) and more than half (61%) of biotherapeutic developers. Extensive data from 434 biopharmaceutical manufacturers in 32 countries is summarized in BioPlan Associates’ just-released 5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.